End of Life: Psychedelics in Palliative Care
We interview Dr. Paul Thielking, Chief Science Officer of Numinus, about the use of psychedelics in palliative care and end of life care
ketamine
Psychedelic South: The Quest to find Good Drugs in Alabama
Moving from San Francisco to Alabama comes with some culture shock, including the inability to find good drugs or a psychedelic community
Finding the Messy Middle with Sex and Psychedelics
Combining sex and psychedelics can be fun and adventurous, but it can also be confusing and overwhelming. What happens in the messy middle?
Psychedelic Clinical Trials and the Michael Pollan Effect
With the incredible popularity of “How to Change Your Mind,” Michael Pollan sells people on psychedelic treatments that are not yet available
Three Phase 3 Clinical Trials that Could Legalize Psychedelics
The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy
Opiate Addiction: Jails, Institutions, Death… and Psychedelics
Psychedelics have the potential to treat the suffering caused by opiate addiction, but treatment is out of reach for those who need it most.
Medical Applications of Ketamine & Common Misconceptions with Christi Myers, Flow Integrative
In this episode, Christi provides insight into how ketamine impacts people’s physical and mental health. She goes into the comparison of ketamine’s effects compared to other psychedelics and how Flow Integrative’s patient care is unique.
Examining Ketamine Therapy with Myriam Barthes, Journey Clinical
In today’s episode, Myriam describes the impact of ketamine on the mind and the body, and specifically how ketamine therapy compares to other psychedelic-assisted therapies.
Psychedelic Business Spotlight – June 3
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind files for a new patent; and much more!
Psychedelic Business Spotlight – May 13
This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.
End of content
End of content